http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
CytoSorbents Expands Distribution and Sales of CytoSorb® to treat Deadly Inflammation in Panama with DRGR
-
Cytosorbents (CTSO) Secures $1M STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma
-
CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma
-
CytoSorbents Receives Additional $5 Million in Non-Dilutive Debt Financing from Bridge Bank
-
CytoSorbents Announces Director and Management Open Market Stock Purchases
-
CytoSorbents - A Leader in Blood Purification to Treat Deadly Inflammation - Teams with Investor Relations Firm LifeSci Advisors
-
Cytosorbents (CTSO) Names Dr. Eric G. Mortensen as Chief Medical Officer
-
Dr. Eric G. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer
-
CytoSorbents Selected to Present at Special Operations SOMSA 2017 Conference and 18th Annual B. Riley & Co. Investor Conference
-
Aferetica and CytoSorbents Extend Exclusive "Life-saving" Partnership through 2021
-
CytoSorbents Reports First Quarter 2017 Financial Results
-
Cytosorbents (CTSO) Presents REFRESH I Trial Results at AATS
-
CytoSorbents Announces Positive REFRESH I Trial Results
-
CytoSorbents to Report Q1 2017 Operating and Financial Results
-
Cytosorbents (CTSO) Granted $1M Phase II SBIR Contract by U.S. DOD to Advance Fungal Mycotoxin Blood Purification
-
CytoSorbents Awarded $1M Phase II SBIR Contract by U.S. Department of Defense to Advance Fungal Mycotoxin Blood Purification
-
CytoSorbents 2017 - Propelling the Company to the "Next Level"
-
Cytosorbents (CTSO) Prices 2.22M Share Follow-On Offering at $4.50
-
CytoSorbents Announces Pricing of Follow-On Offering
-
Cytosorbents (CTSO) to Offer Common Stock
-
CytoSorbents Announces Proposed Offering of Common Stock
-
CytoSorbents Strengthens Intellectual Property Portfolio with New Patents Issued in the U.S., China, Japan, Russia, and Australia
-
Cytosorbents (CTSO) Announces REFRESH I Trial Abstract Selected for Podium Presentation at AATS
-
CytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference
-
Dr. Carl H. June, Cancer Immunotherapy Pioneer, Joins CytoSorbents Scientific Advisory Board
-
CytoSorb® Treatment of HLH - The Parallel to Cytokine Release Syndrome in Cancer Immunotherapy
-
Cytosorbents (CTSO) Reports CytoSorb® Partnership with Dr. Reddy's Laboratories
-
CytoSorbents Announces CytoSorb® Partnership with Dr. Reddy's Laboratories
-
CytoSorbents Highlights Activities at the 22nd International Conference on Advances in Critical Care Nephrology
-
CytoSorbents to Present at the Maxim Group - Haitong Securities Inaugural Healthcare Investor and Partnering Conference
-
CytoSorbents Reports Record Quarterly and Full-Year 2016 Revenue
-
CytoSorbents to Present at 37th Annual Cowen and Company Healthcare Conference
-
CytoSorbents to Report Fiscal 2016 Operating and Financial Results
-
CytoSorbents to Present at the 19th Annual BIO CEO & Investor Conference
-
CytoSorbents Launches VetResQ™ for U.S. Veterinary Market
-
CytoSorbents Pre-announces Q4 2016 and Full-Year 2016 Results
-
Fresenius Medical Care and CytoSorbents Expand Original Partnership and Add New Co-Marketing Agreement for Worldwide CytoSorb® Markets
-
CytoSorbents To Provide Corporate Update at Biotech Showcase 2017
-
Cytosorbents (CTSO) Announces Launch and Initial Sales of New CytoSor
-
CytoSorbents Announces First Sales of New CytoSorb® CPB Procedure Pack for Cardiac Surgery
-
CytoSorbents Receives $318,551 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
-
CytoSorb® Attains Permanent, Dedicated Reimbursement Code in Core Market of Germany
-
CytoSorbents to Present at the LD Micro Main Event Investor Conference
-
CytoSorb® Selected for NICE MedTech Innovation Briefing in the United Kingdom
-
First Successful Treatment of Dengue Fever and Dengue Shock Syndrome Using CytoSorb®
-
CytoSorbents Reports Highlights from the SepsEast 2016 Critical Care Congress
-
Adrian Thomas Joins CytoSorbents to Drive Western European Sales
-
CytoSorb® Q3 2016 Sales Reach Record $2.14M, Doubling From a Year Ago
-
CytoSorbents Expands Direct Sales of CytoSorb to Belgium and Luxembourg
-
CytoSorbents to Report Q3 2016 Operating and Financial Results

